We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
+$34.2M
Cap. Flow %
1.92%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.24%
2 Healthcare 10.61%
3 Energy 0.15%
4 Communication Services 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
176
PUT
DELISTED
Medicines Co
MDCO
$523K 0.03%
+184
New +$6.09K
TCRT icon
177
Alaunos Therapeutics
TCRT
$3.84M
$506K 0.03%
+737
New +$494K
CATX icon
178
Perspective Therapeutics
CATX
$333M
$496K 0.03%
22,538
-39,615
-64% -$403K
PRTA icon
179
PUT
Prothena Corp
PRTA
$458M
$479K 0.03%
+125
New +$4.03K
AGEN
180
CALL
Agenus
AGEN
$312M
$477K 0.03%
77
+62
+413% +$4.31K
LUMO
181
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$472K 0.03%
+18
New +$5.5K
MNTA
182
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$445K 0.02%
382
+250
+189% +$4.23K
EXEL icon
183
PUT
Exelixis
EXEL
$13.9B
$430K 0.02%
1,216
+867
+248% +$5.9K
TSRO
184
CALL
DELISTED
TESARO, Inc.
TSRO
$413K 0.02%
+140
New +$4.41K
ENTA icon
185
CALL
Enanta Pharmaceuticals
ENTA
$377M
$408K 0.02%
+102
New +$3.71K
NWBO
186
CALL
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$399K 0.02%
551
+433
+367% +$2.57K
DMK
187
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$386K 0.02%
868
-4,947
-85% -$2.24M
ACHN
188
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$376K 0.02%
1,142
-349
-23% -$1.22K
ECYT
189
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$367K 0.02%
154
+47
+44% +$681
EOCN
190
Eocene Ltd. Ordinary Shares
EOCN
$4.1M
$360K 0.02%
+22
New +$412K
RXII
191
CALL
DELISTED
GALENA BIOPHARMA INC COM
RXII
$350K 0.02%
1,400
-30
-2% -$7.5K
ATHX
192
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$339K 0.02%
42
+23
+121% +$2.13K
HZNP
193
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$331K 0.02%
219
+108
+97% +$1.22K
PGNX
194
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$324K 0.02%
+794
New +$4.06K
TCRT icon
195
CALL
Alaunos Therapeutics
TCRT
$3.84M
$316K 0.02%
5
-12
-71% -$8.04K
ADXS
196
PUT
DELISTED
Advaxis Inc
ADXS
$314K 0.02%
+67
New +$4.73K
SEEL
197
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
WINT
198
CALL
DELISTED
Windtree Therapeutics Inc
WINT
$304K 0.02%
101
+94
+1,343% +$3.16K
IMUC
199
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$293K 0.02%
60
-33
-35% -$1.61K
OREX
200
DELISTED
Orexigen Therapeutics, Inc.
OREX
$291K 0.02%
+4,478
New +$303K
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management's Q1 2014 filing shows 107 new, 59 increased, 54 reduced and 92 closed positions. Its largest new stake was Tenax Therapeutics: 66 shares worth $11.8M. The largest sale was MannKind Corp, an estimated $22.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Energy.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.